Anti-IL-12 antibodies and compositions
The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
1. An isolated anti-IL-12 antibody, comprising a heavy chain complementarity determining region 1 (CDR1) of the amino acid sequence set forth in SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) of the amino acid sequence set forth in SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) of the amino acid sequence set forth in SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) of the amino acid sequence set forth in SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) of the amino acid sequence set forth in SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) of the amino acid sequence set forth in SEQ ID NO:6.
2. The anti-IL-12 antibody according to claim 1 , wherein said antibody binds IL-12 with an affinity of at least one selected from at least 10 −9 M, at least 10 −10 M, at least 10 −11 M, or at least 10 −12 M.
3. The anti-IL-12 antibody according to claim 1 , wherein said antibody neutralizes an activity of IL-12 protein.
4. A composition comprising an isolated anti-IL-12 antibody having a heavy chain complementarity determining region 1 (CDR1) of the amino acid sequence set forth in SEQ ID NO:1, a heavy chain complementarity determining region 2 (CDR2) of the amino acid sequence set forth in SEQ ID NO:2, a heavy chain complementarity determining region 3 (CDR3) of the amino acid sequence set forth in SEQ ID NO:3, a light chain complementarity determining region 1 (CDR1) of the amino acid sequence set forth in SEQ ID NO:4, a light chain complementarity determining region 2 (CDR2) of the amino acid sequence set forth in SEQ ID NO:5, and a light chain complementarity determining region 3 (CDR3) of the amino acid sequence set forth in SEQ ID NO:6, and at least one pharmaceutically acceptable carrier or diluent.